Bristol Myers Squibb

News

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

BMS buys Asian rights to key growth drug Camzyos

Bristol-Myers Squibb has decided it wants complete, worldwide control of cardiovascular drug mavacamten, tipped as a future blockbuster, so it has paid $350 million to sho

News

ESMO: Immunotherapy combos extend lives in bladder cancer

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.

News

ESMO: Opdivo chases Keytruda in perioperative lung cancer

Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a

News

Pfizer launches cost-cutting drive as COVID sales fall

Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e

Bayer doubles down on Factor XIa with new phase 3 trial

ESMO: J&J’s Tagrisso challenge, and other highlights

BMS buys Asian rights to key growth drug Camzyos

ESMO: Immunotherapy combos extend lives in bladder cancer

ESMO: Opdivo chases Keytruda in perioperative lung cancer

Pfizer launches cost-cutting drive as COVID sales fall

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Bristol Myers Squibb

Editor's Picks